About Aratana Therapeutics (NASDAQ:PETX)
Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PETX
CUSIPN/A
Phone913-353-1000
Debt
Debt-to-Equity Ratio0.24%
Current Ratio2.40%
Quick Ratio2.02%
Price-To-Earnings
Trailing P/E Ratio-5.12
Forward P/E Ratio-8.15
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.57 million
Price / Sales8.91
Cash FlowN/A
Price / CashN/A
Book Value$1.86 per share
Price / Book2.67
Profitability
EPS (Most Recent Fiscal Year)($0.97)
Net Income$-47,510,000.00
Net Margins-185.78%
Return on Equity-45.15%
Return on Assets-28.23%
Miscellaneous
Employees85
Outstanding Shares45,850,000
Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions
What is Aratana Therapeutics' stock symbol?
Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."
How were Aratana Therapeutics' earnings last quarter?
Aratana Therapeutics Inc (NASDAQ:PETX) released its earnings results on Tuesday, March, 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.23) by $0.04. The biopharmaceutical company had revenue of $10.46 million for the quarter, compared to the consensus estimate of $5.72 million. Aratana Therapeutics had a negative return on equity of 45.15% and a negative net margin of 185.78%. View Aratana Therapeutics' Earnings History.
When is Aratana Therapeutics' next earnings date?
What price target have analysts set for PETX?
6 brokerages have issued 12-month price objectives for Aratana Therapeutics' stock. Their forecasts range from $8.00 to $10.00. On average, they anticipate Aratana Therapeutics' share price to reach $8.8333 in the next year. View Analyst Ratings for Aratana Therapeutics.
What are Wall Street analysts saying about Aratana Therapeutics stock?
Here are some recent quotes from research analysts about Aratana Therapeutics stock:
- 1. According to Zacks Investment Research, "Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. " (3/7/2018)
- 2. HC Wainwright analysts commented, "Galliprant Approved in EU; Additional Product Approvals Expected in 2018; Reiterate Buy Galliprant approved for canine osteoarthritis in Europe. On January 11, Aratana announced that the EMA has granted Galliprant marketing approval for the treatment of pain associated with mild to moderate osteoarthritis in dogs. Galliprant is licensed to Elanco, the animal health division of Eli Lilly (LLY; not rated), who has exclusive rights to commercialize the drug globally. Galliprant was first approved in the US in March 2016, and in the nine months ended September 30, 2017, generated approximately $9M in product sales and $4M in license and collaboration revenue for Aratana. Going forward, Elanco has assumed all development, regulatory and manufacturing responsibilities for Galliprant, and we expect the company to launch the drug in Europe in 2Q18." (1/16/2018)
Who are some of Aratana Therapeutics' key competitors?
Some companies that are related to Aratana Therapeutics include Concert Pharmaceuticals (CNCE), Sinovac Biotech (SVA), Innate Pharma (IPHYF), Isotechnika Pharma (AUPH), ProMetic Life Sciences (PFSCF), Depomed (DEPO), Synergy Pharmaceuticals (SGYP), Syros Pharmaceuticals (SYRS), Paratek Pharmaceuticals (PRTK), Cytokinetics (CYTK), Cara Therapeutics (CARA), Kala Pharmaceuticals (KALA), Corium International (CORI), Albireo Pharma (ALBO), Mersana Therapeutics (MRSN), Durect (DRRX), Strongbridge Biopharma (SBBP) and Corbus Pharmaceuticals (CRBP).
Who are Aratana Therapeutics' key executives?
Aratana Therapeutics' management team includes the folowing people:
- Wendy L. Yarno, Chairman of the Board (Age 63)
- Steven St. Peter M.D., President, Chief Executive Officer, Director (Age 49)
- Craig A. Tooman, Chief Financial Officer, Treasurer (Age 49)
- Brent Standridge, Chief Operating Officer (Age 58)
- Ernst Heinen Ph.D., Chief Development Officer (Age 52)
- Laura A. Brege, Independent Director (Age 59)
- David L. Brinkley, Independent Director (Age 57)
- Robert Benthall Gerber Jr., Independent Director (Age 52)
- Irvine O. Hockaday Jr. Esq., Independent Director (Age 81)
- Merilee Raines, Independent Director (Age 61)
Has Aratana Therapeutics been receiving favorable news coverage?
Press coverage about PETX stock has been trending somewhat positive on Thursday, according to Accern. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aratana Therapeutics earned a coverage optimism score of 0.09 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 44.49 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Aratana Therapeutics?
Shares of PETX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aratana Therapeutics' stock price today?
One share of PETX stock can currently be purchased for approximately $4.97.
How big of a company is Aratana Therapeutics?
Aratana Therapeutics has a market capitalization of $237.53 million and generates $25.57 million in revenue each year. The biopharmaceutical company earns $-47,510,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Aratana Therapeutics employs 85 workers across the globe.
How can I contact Aratana Therapeutics?
Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]
MarketBeat Community Rating for Aratana Therapeutics (PETX)
MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe PETX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aratana Therapeutics (NASDAQ:PETX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Aratana Therapeutics in the last 12 months. Their average twelve-month price target is $8.8333, suggesting that the stock has a possible upside of 77.73%. The high price target for PETX is $10.00 and the low price target for PETX is $8.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 2.83 | 2.67 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $8.8333 | $8.50 | $8.75 | $8.3333 |
| Price Target Upside: | 77.73% upside | 110.40% upside | 67.62% upside | 55.18% upside |
Aratana Therapeutics (NASDAQ:PETX) Consensus Price Target History
Aratana Therapeutics (NASDAQ:PETX) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Aratana Therapeutics (NASDAQ:PETX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Aratana Therapeutics (NASDAQ PETX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.20%
Institutional Ownership Percentage: 66.65%
Aratana Therapeutics (NASDAQ PETX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/30/2018 | Peter Steven St | CEO | Sell | 19,367 | $4.77 | $92,380.59 | 672,259 |  |
| 1/11/2018 | Craig A Tooman | Insider | Sell | 30,000 | $5.27 | $158,100.00 | 75,024 | |
| 12/1/2017 | Healthcare Master Fun Broadfin | Major Shareholder | Sell | 890,516 | $5.70 | $5,075,941.20 | | |
| 11/29/2017 | Healthcare Master Fun Broadfin | Major Shareholder | Sell | 116,516 | $6.53 | $760,849.48 | | |
| 11/10/2017 | Peter Steven St | Insider | Sell | 50,000 | $7.00 | $350,000.00 | 529,359 | |
| 10/2/2017 | Peter Steven St | Insider | Sell | 50,000 | $6.24 | $312,000.00 | | |
| 9/25/2017 | Brent Standridge | COO | Sell | 10,000 | $6.11 | $61,100.00 | 70,267 | |
| 9/15/2017 | Ernst Heinen | Insider | Sell | 10,000 | $6.25 | $62,500.00 | 130,994 | |
| 4/17/2017 | Peter Steven St | Insider | Sell | 50,000 | $5.54 | $277,000.00 | 582,693 | |
| 1/27/2017 | Peter Steven St | Insider | Sell | 50,000 | $7.72 | $386,000.00 | 632,693 | |
| 12/15/2016 | Peter Steven St | Insider | Sell | 50,000 | $7.63 | $381,500.00 | 592,793 | |
| 10/3/2016 | Ernst Heinen | Insider | Sell | 10,000 | $10.00 | $100,000.00 | 115,494 | |
| 9/9/2016 | Craig A Tooman | Insider | Sell | 30,000 | $9.25 | $277,500.00 | 72,424 | |
| 8/9/2016 | Peter Steven St | Insider | Sell | 50,000 | $9.25 | $462,500.00 | 642,793 | |
| 6/28/2016 | Julia A Stephanus | Insider | Sell | 30,000 | $6.25 | $187,500.00 | 127,503 | |
| 6/17/2016 | Peter Steven St | CEO | Sell | 100,000 | $6.26 | $626,000.00 | 717,793 | |
| 6/10/2016 | Ernst Heinen | Insider | Sell | 15,000 | $6.72 | $100,800.00 | 125,494 | |
| 2/1/2016 | Craig A Tooman | CFO | Sell | 2,806 | $3.36 | $9,428.16 | 102,424 | |
| 11/9/2015 | Craig A Tooman | CFO | Sell | 3,620 | $7.52 | $27,222.40 | 69,980 | |
| 10/2/2015 | Craig A Tooman | CFO | Sell | 3,250 | $8.06 | $26,195.00 | 73,600 | |
| 7/15/2015 | Ernst Heinen | Insider | Sell | 15,000 | $17.06 | $255,900.00 | | |
| 4/27/2015 | Linda Rhodes | Insider | Sell | 15,000 | $15.00 | $225,000.00 | | |
| 3/6/2015 | Linda Rhodes | Insider | Sell | 20,000 | $20.00 | $400,000.00 | | |
| 3/6/2015 | Vort John Vander | Director | Sell | 6,137 | $20.01 | $122,801.37 | | |
| 1/13/2015 | Julia A Stephanus | Insider | Sell | 6,300 | $19.00 | $119,700.00 | | |
| 1/13/2015 | Peter Steven St | CEO | Sell | 75,000 | $19.23 | $1,442,250.00 | | |
| 12/22/2014 | Linda Rhodes | Insider | Sell | 10,000 | $18.00 | $180,000.00 | | |
| 7/3/2014 | Julia A Stephanus | Insider | Sell | 2,000 | $17.33 | $34,660.00 | | |
| 7/1/2014 | Linda Rhodes | Insider | Sell | 10,000 | $16.00 | $160,000.00 | | |
| 6/17/2014 | Linda Rhodes | Insider | Sell | 4,626 | $15.00 | $69,390.00 | | |
| 6/16/2014 | Julia A Stephanus | Insider | Sell | 8,000 | $13.90 | $111,200.00 | | |
| 6/2/2014 | Peter Steven St | CEO | Sell | 25,000 | $13.47 | $336,750.00 | | |
| 5/5/2014 | Ernst Heinen | Insider | Sell | 10,000 | $13.42 | $134,200.00 | 95,294 | |
| 2/3/2014 | Ronald Meeusen | Director | Sell | 500,000 | $19.00 | $9,500,000.00 | | |
| 7/2/2013 | Julia A Stephanus | Insider | Buy | 2,000 | $6.00 | $12,000.00 | | |
| 7/2/2013 | Peter Steven St | CEO | Buy | 8,333 | $6.00 | $49,998.00 | | |
| 7/2/2013 | Ventures Ix L.P. Avalon | Major Shareholder | Buy | 500,000 | $6.00 | $3,000,000.00 | | |
(Data available from 1/1/2013 forward)
Aratana Therapeutics (NASDAQ PETX) News Headlines
| Source: |
|
Aratana Therapeutics (NASDAQ:PETX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aratana Therapeutics (NASDAQ:PETX) Income Statement, Balance Sheet and Cash Flow Statement
Aratana Therapeutics (NASDAQ PETX) Stock Chart for Thursday, April, 19, 2018
Loading chart…
